Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Moving forward a breadth of assets to drive long-term growth
3 INNOVATION
Selected opportunities, expected 2021 milestones and additional indications
Lifecycle management
Pharmaceuticals
EntrestoⓇ
China approval for essential
hypertension
Iptacopan
(LNP023)
IgAN, PNH, C3G, aHUS:
Ph3 start 2021
Oncology
Canakinumab
(ACZ885)
NSCLC 1L: CANOPY-1
Ph3 readout H2 2021
NSCLC adjuvant
iMN
HS: SUNRISE, SUNSHINE
Ph3 readout H2 2021
177 Lu-PSMA-617
mCRPC 3L: VISION positive
readout; submission H2 2021
Cosentyx®
L. Planus, jPsA/ERA (submitted),
Iscalimab
(CFZ533)
Sjögren's, kidney Tx, liver Tx
GCA, lupus nephritis
aBC: MONALEESA-2 OS
readout H2 2021
KisqaliⓇ
Ligelizumab
(QGE031)
CSU: PEARL 1, 2
Ph3 readout H2 20211
HR+/HER2- BC (adj) readout 2022
CINDU, food allergy
Ph3 start H2 2021
Hyperlipidemia: resubmitted to FDA
LeqvioⓇ
CVRR-LDLC
ZolgensmaⓇ SMA IT
Pelacarsen
(TQJ230)
Branaplam
(LMI070)
HD: Ph2b start H2 2021
CVRR-Lp(a)
TNO155
combinations
Tislelizumab
(VDT482)
Sabatolimab
(MBG453)
mCRPC pre-taxane, mHSPC:
Ph3s started
HR-MDS: STIMULUS
Ph2 continues blinded after
CR readout²
AML
Solid tumors, multiple
combinations being explored
in ongoing trials
2L esophageal cancer and
NSCLC: submission 2021
'Wild Cards'
Asciminib (CML 1L: Ph3 start H2 2021), LNA043 (Osteoarthritis: Ph2b started H1 2021), CSJ117 (Asthma), QBW251 (COPD), LXH254
(BRAF/NRASM melanoma, mRAS/RAF NSCLC), NIS793 (Solid tumors, mPDAC Ph3 start H2 2021)
1. Q4/2021-Q1/2022 potential COVID-19 impact. 2. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial.
10 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation